(Q36422849)

14 August 2017

1 reference

title

Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors (English)

1 reference

14 August 2017

0 references

1 reference

1 reference

1

Dajing Xia

1 reference

14 August 2017

Terence Moyana

2

1 reference

14 August 2017

Jim Xiang

series ordinal

3

1 reference

14 August 2017

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

16

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

241-259

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cr.7310032

14 August 2017

exact match

0 references

cites work

Cancer: the rise of the genetic paradigm

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Clinical applications of dendritic cell vaccination in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Progress and potential for gene-based medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Gene therapy insertional mutagenesis insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Genomic Instability and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

New insights into p53 regulation and gene therapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Negative regulators of cyclin-dependent kinases and their roles in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Interaction between p53 and p16 expressed by adenoviral vectors in human malignant glioma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Influence of the bystander effect on HSV-tk/GCV gene therapy. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenoviral-mediated suicide gene therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Genomic DNA released by dying cells induces the maturation of APCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Molecular events of bacterial-induced maturation of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

The generation of anti-tumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cells resurrect antigens from dead cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cell-dead cell interactions: implications and relevance for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

A receptor for phosphatidylserine-specific clearance of apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

The induction of tolerance by dendritic cells that have captured apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Transfected human dendritic cells to induce antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Gene-modified dendritic cells for use in tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

IL-12: a key cytokine in immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Secondary lymphoid-tissue chemokine induced modulation of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intensity of the vaccine-elicited immune response determines tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Cutting Edge: Intravenous Soluble Antigen Is Presented to CD4 T Cells by CD8- Dendritic Cells, but Cross-Presented to CD8 T Cells by CD8+ Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

Gene transfer technology in therapy: current applications and future goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Recovery of new agent from patients with acute respiratory illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

CD16+ and CD16− human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Dendritic cell-based vaccines in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

CD91: a receptor for heat shock protein gp96

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Efficient nonviral transfection of dendritic cells and their use for in vivo immunization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Enhanced transgene expression and effective in vivo antitumor immune responses initiated by dendritic progenitors transfected with a nonviral T7 vector expressing a model tumor antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Adenovirus-Mediated MUC1 gene transduction into human blood-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Enhanced Dendritic Cell Maturation by TNF- or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Dendritic cells require T cells for functional maturation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310032

7 January 2021

Identifiers

DOI

10.1038/SJ.CR.7310032

1 reference

14 August 2017

1 reference